Literature DB >> 33490036

Multi-Targeted Anticancer Activity of Imidazolate Phosphane Gold(I) Compounds by Inhibition of DHFR and TrxR in Breast Cancer Cells.

Rossana Galassi1, Lorenzo Luciani1, Valentina Gambini2, Silvia Vincenzetti2, Giulio Lupidi3, Augusto Amici2, Cristina Marchini2, Junbiao Wang2, Stefania Pucciarelli2.   

Abstract

A class of phosphane gold(I) compounds, made of azoles and phosphane ligands, was evaluated for a screening on the regards of Breast Cancer cell panels (BC). The compounds possess N-Au-P or Cl-Au-P bonds around the central metal, and they differ for the presence of aprotic or protic polar groups in the azoles and/or the phosphane moieties to tune their hydrophilicity. Among the six candidates, only the compounds having the P-Au-N environment and not displaying neither the hydroxyl nor carboxyl groups in the ligands were found active. The compounds were screened by MTT tests in SKBR3, A17, and MDA-MB231 cancer cells, and two compounds (namely the 4,5-dicyano-imidazolate-1yl-gold(I)-(triphenylphosphane, 5, and 4,5-dichloro-imidazolate-1yl-gold(I)-triphenylphosphane, 6) were found very cytotoxic, with the most active with an IC50 value of 3.46 μM in MDA-MB231 cells. By performing enzymatic assays in the treated cells lysates, the residual enzymatic activity of dihydrofolate reductase (DHFR) has been measured after cell treatment for 4 or 12 h in comparison with control cells. Upon 12 h of treatment, the activity of DHFR was significantly reduced in both SKBR3 and A17 cells by compounds 5 and 6, but not in human MDA-MB231 cells; interestingly, it was found remarkably high after 4 h of treatment, revealing a time dependence for the DHFR enzymatic assays. The DHFR inhibition data have been compared to those for the thioredoxin reductase (TrxR), the most recognized molecular target for gold compounds. For this latter, similar residual activities (i.e., 37 and 49% for the match of SKBR3 cells and compound 5 or 6, respectively) were found. Binding studies on the regards of ct-DNA (calf-thymus-DNA) and of plasma transporters proteins, such as BSA (bovine serum albumin) and ATF (apo transferrin), were performed. As expected for gold compounds, the data support strong binding to proteins (Ksv values range: 1.51 ÷ 2.46 × 104 M-1) and a weaker interaction with ct-DNA's minor groove (Ksv values range: 1.55 ÷ 6.12 × 103 M-1).
Copyright © 2021 Galassi, Luciani, Gambini, Vincenzetti, Lupidi, Amici, Marchini, Wang and Pucciarelli.

Entities:  

Keywords:  DiHydroFolateReductase; anticancer agents; breast cancer; enzyme inhibition; gold; gold phosphane compounds; metal based drug; thioredoxinReductase

Year:  2021        PMID: 33490036      PMCID: PMC7821381          DOI: 10.3389/fchem.2020.602845

Source DB:  PubMed          Journal:  Front Chem        ISSN: 2296-2646            Impact factor:   5.221


  51 in total

Review 1.  Serum transferrin receptor assays and their application.

Authors:  Mark Worwood
Journal:  Ann Clin Biochem       Date:  2002-05       Impact factor: 2.057

2.  Distinct roles for Sp1 and E2F sites in the growth/cell cycle regulation of the DHFR promoter.

Authors:  D E Jensen; A R Black; A G Swick; J C Azizkhan
Journal:  J Cell Biochem       Date:  1997-10-01       Impact factor: 4.429

Review 3.  Gold(III) complexes in medicinal chemistry.

Authors:  Pedro Ivo da Silva Maia; Victor M Deflon; Ulrich Abram
Journal:  Future Med Chem       Date:  2014-09       Impact factor: 3.808

Review 4.  On the potential of thioredoxin reductase inhibitors for cancer therapy.

Authors:  Sabine Urig; Katja Becker
Journal:  Semin Cancer Biol       Date:  2006-09-26       Impact factor: 15.707

Review 5.  A perspective on anti-EGFR therapies targeting triple-negative breast cancer.

Authors:  Katsuya Nakai; Mien-Chie Hung; Hirohito Yamaguchi
Journal:  Am J Cancer Res       Date:  2016-08-01       Impact factor: 6.166

6.  Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15.

Authors:  B Fisher; A M Brown; N V Dimitrov; R Poisson; C Redmond; R G Margolese; D Bowman; N Wolmark; D L Wickerham; C G Kardinal
Journal:  J Clin Oncol       Date:  1990-09       Impact factor: 44.544

Review 7.  Gold compounds as anticancer agents: chemistry, cellular pharmacology, and preclinical studies.

Authors:  Stefania Nobili; Enrico Mini; Ida Landini; Chiara Gabbiani; Angela Casini; Luigi Messori
Journal:  Med Res Rev       Date:  2010-05       Impact factor: 12.944

8.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

Review 9.  Triple-negative breast cancer: is there a treatment on the horizon?

Authors:  Hui Yao; Guangchun He; Shichao Yan; Chao Chen; Liujiang Song; Thomas J Rosol; Xiyun Deng
Journal:  Oncotarget       Date:  2017-01-03

Review 10.  DHFR Inhibitors: Reading the Past for Discovering Novel Anticancer Agents.

Authors:  Maria Valeria Raimondi; Ornella Randazzo; Mery La Franca; Giampaolo Barone; Elisa Vignoni; Daniela Rossi; Simona Collina
Journal:  Molecules       Date:  2019-03-22       Impact factor: 4.411

View more
  4 in total

Review 1.  Bioactivity and Development of Small Non-Platinum Metal-Based Chemotherapeutics.

Authors:  Maria Grazia Ferraro; Marialuisa Piccolo; Gabriella Misso; Rita Santamaria; Carlo Irace
Journal:  Pharmaceutics       Date:  2022-04-28       Impact factor: 6.525

2.  Novel Au Carbene Complexes as Promising Multi-Target Agents in Breast Cancer Treatment.

Authors:  Jessica Ceramella; Annaluisa Mariconda; Marco Sirignano; Domenico Iacopetta; Camillo Rosano; Alessia Catalano; Carmela Saturnino; Maria Stefania Sinicropi; Pasquale Longo
Journal:  Pharmaceuticals (Basel)       Date:  2022-04-21

3.  Coinage Metal Compounds With 4-Methoxy-Diphenylphosphane Benzoate Ligand Inhibit Female Cancer Cell Growth.

Authors:  Lorenzo Luciani; Rossana Galassi; Junbiao Wang; Cristina Marchini; Alessia Cogo; Maria Luisa Di Paolo; Lisa Dalla Via
Journal:  Front Chem       Date:  2022-07-13       Impact factor: 5.545

Review 4.  Breast Cancer Treatment: The Case of Gold(I)-Based Compounds as a Promising Class of Bioactive Molecules.

Authors:  Rossana Galassi; Lorenzo Luciani; Junbiao Wang; Silvia Vincenzetti; Lishan Cui; Augusto Amici; Stefania Pucciarelli; Cristina Marchini
Journal:  Biomolecules       Date:  2022-01-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.